This MedLibrary.org supplementary page on Y-23684 is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Y-23684
|
|
| Systematic (IUPAC) name | |
| 2-(4-Chlorophenyl)-5,6-dihydro-[1]benzothepino[5,4-c]pyridazin-3(2H)-one-7-oxide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C18H13ClN2O2S |
| Mol. mass | 356.826 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Y-23684 is an anxiolytic drug with a novel chemical structure, which is used in scientific research.[1][2] It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.
Y-23684 is a nonselective partial agonist at GABAA receptors. It has primarily anxiolytic and anticonvulsant effects, with sedative and muscle relaxant effects only appearing at higher doses. It produces little ataxia or potentiation of other sedatives such as ethanol or barbiturates when compared to the benzodiazepines diazepam and clobazam in animal tests.[3][4][5]
Y-23684 has a favourable pharmacological profile, producing strong anxiolytic and moderate anticonvulsant effects at low doses that cause little or no sedative side effects. It has been proposed for development for human medical use, but has not yet gone beyond animal tests.[6]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Nakao T, Obata M, Kawakami M, Morita K, Tanaka H, Morimoto Y, Takehara S, Yakushiji T, Tahara T. Studies on the synthesis of condensed pyridazine derivatives. IV. Synthesis and anxiolytic activity of 2-aryl-5,6-dihydro-(1)benzothiepino[5,4- c]pyridazin-3(2H)-ones and related compound. Chemical and Pharmaceutical Bulletin (Tokyo). 1991 Oct;39(10):2556-63.
- ^ Nakao T, Obata M, Yamaguchi Y, Marubayashi N, Ikeda K, Morimoto Y. Synthesis and biological activities of optical isomers of 2-(4-chlorophenyl)-5,6-dihydro-(1)benzothiepino[5,4-c]pyridazin-3(2H)-one-7-oxide. Chemical and Pharmaceutical Bulletin (Tokyo). 1992 Jan;40(1):117-21.
- ^ Yakushiji T, Shirasaki T, Munakata M, Hirata A, Akaike N. Differential properties of type I and type II benzodiazepine receptors in mammalian CNS neurones. British Journal of Pharmacology. 1993 Jul;109(3):819-25.
- ^ Yasumatsu H, Morimoto Y, Yamamoto Y, Takehara S, Fukuda T, Nakao T, Setoguchi M. The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. British Journal of Pharmacology. 1994 Apr;111(4):1170-8.
- ^ Griebel G, Perrault G, Sanger DJ. Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice. Pharmacology, Biochemistry and Behaviour. 1999 Apr;62(4):689-94.
- ^ Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ. Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. Behavioural Pharmacology. 1999 Sep;10(5):483-95.
|
||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 18 June 2008, at 23:51.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Y-23684".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.